Company Overview
Alpa Laboratories Limited (BSE: 532878, NSE: ALPA) reported its financial results for FY 2025-26 and convened its 38th Annual General Meeting on September 30, 2026 via video conference.
Financial Performance
FY26 standalone sales decreased 10.5% to ₹12,153.02 lakhs from ₹13,575.71 lakhs in FY25, with net profit declining 29% to ₹1,406.91 lakhs from ₹1,982.90 lakhs. Consolidated performance showed similar trends with sales of ₹12,156.64 lakhs and net profit of ₹1,412.59 lakhs. Basic EPS stood at ₹6.71 compared to ₹9.34 in the previous year. Key financial ratios showed significant deterioration including Return on Equity declining to 8% from 12% and Net Profit Ratio falling to 13% from 17%.
AGM Resolutions
The AGM addressed ordinary business including adoption of financial statements and re-appointment of Mr. Mahendra Singh Chawla as director. Special business included ratification of cost auditor remuneration, appointment of Mrs. Radhika Biyani as Independent Director for 5 years, approval for loans/guarantees/investments up to ₹160 crores, and re-appointment of Mr. Paresh Chawla as Managing Director for 5 years.
Capital and Dividend
No dividend was recommended for FY26 to conserve resources for future growth, operations strengthening, R&D initiatives, and potential acquisitions. The paid-up equity share capital remained unchanged at ₹2,104.06 lakhs with 99.98% held in dematerialized form.
Operational Highlights
Revenue from sale of manufactured goods was ₹10,414.12 lakhs while stock-in-trade contributed ₹77.68 lakhs. Cost of materials consumed decreased to ₹6,325.37 lakhs from ₹7,071.93 lakhs. Employee benefits expense increased to ₹1,580.68 lakhs. The company maintained significant investments including ₹7,050.97 lakhs in mutual funds and ₹3,631.38 lakhs in debentures.
Subsidiaries and Associates
Norfolk Mercantile Private Limited, the wholly-owned subsidiary, reported a loss of ₹3.40 lakhs. The company holds 18% share in Seabright Landmark Projects LLP and invested ₹150 lakhs during the year. A scheme of merger with Alpa Laboratories Limited is pending before NCLT, Mumbai Bench.
Corporate Governance and Compliance
The Board met 4 times during FY26 with all directors attending all meetings. CSR expenditure significantly exceeded requirements at ₹80.21 lakhs against mandated ₹19.85 lakhs, primarily benefiting Shree Hiraba Charitable Trust for education initiatives. Total assets pledged as security amounted to ₹6,916.26 lakhs, comprising current assets of ₹5,416.35 lakhs and non-current assets of ₹1,499.91 lakhs.
Contingencies and Outlook
Contingent liabilities include disputed sales tax dues of ₹57.57 lakhs, disputed income tax dues of ₹599.41 lakhs, and guarantees to banks/FIs of ₹710.49 lakhs. The board approved exploring incorporation of overseas company "Alpa Biopharm Limited" in Nigeria in association with Blueseal Pharmaceuticals Limited, subject to statutory approvals.